

## MiRXES announces Southeast Asia's first business and clinical advisory programme

25 October 2022 | News

**To accelerate revenue growth of startups and adoption of preventive healthcare solutions globally**



MiRXES, a Singapore-headquartered biotechnology company focused on saving lives and improving health economics and outcomes through RNA-powered disease early detection and precision genomic tests, has launched the first edition of MiRXES Translator Programme, Southeast Asia's first business and clinical advisory programme backed by science that bridges post-incubation ideation and post-accelerator growth, at Singapore Week of Innovation and Technology (SWITCH), being held from 25 to 28 October.

Through this investor-partner partnership, MiRXES will play an active role to co-generate measurable business milestones and results while sharing risks and rewards with companies enrolled in the programme, resulting in assisting them to grow and scale their business efficiently and effectively. MiRXES will also enable the acceleration of their growth by contributing its research, manufacturing and clinical diagnostic capabilities to validate products and provide cost advantage through economies of scale, facilitating partnership between venture funds, medical partners, government, hospitals and adopters, as well as providing a platform at MiRXES's Early Medical Centre for the commercialisation of solutions. These companies will also receive support from MiRXES in the regionalisation of their businesses through MiRXES's infrastructures in Southeast Asia.

Plug and Play, a highly successful investor and preferred innovation partner for major corporations, will assess applicants and curate suitable emerging preventive health-focused technology startups for the MiRXES Translator Programme. MiRXES will collaborate with the shortlisted startups to run an extensive programme to develop and enhance their reach within the preventive healthcare sector. Depending on the startup's maturity, the collaboration could span across solution optimisation, pilot production, clinical advisory and market validation.